Speakers Articles

Symposium Pictures
Symposium Report
Kinase Links
Speakers Articles
- Dr. Kari Alitalo: Vascular Endothelial Growth Factor Receptor 3 Is Involved in Tumor Angiogenesis and Growth

- Prof. Mariano Barbacid: Cell cycle kinases in cancer

- Prof. David Barford: Identification of Inhibitors of Protein Kinase B Using Fragment-Based Lead Discovery

- Prof. David Barford: A Structural Comparison of Inhibitor Binding to PKB, PKA and PKA-PKB Chimera

- Prof. David Barford: Wild-Type and Mutant B-RAF Activate C-RAF through Distinct Mechanisms Involving Heterodimerization

- Prof. David Barford: Crystal structure of an activated Akt/Protein Kinase B ternary complax with GSK3-peptide and AMP-PNP

- Véronique Calleja: Intra- and inter-molecular interactions of Protein Kinase B define its activation in vivo

- Prof. Philip Cohen: The twentieth century struggle to decipher insulin signalling

- Prof. Sara A. Courtneidge: The adaptor protein Tks5/Fish is required for podosome formation and function, and for the protease-driven invasion of cancer cells

- Dr. Sandra Jacob: Second generation inhibitors of BCRABL for the treatment of imatinibresistant chronic myeloid leukaemia

- Dr. Sandra Jacob: The Crystal Structure of a c-Src Complex in an Active Conformation Suggests Possible Steps in c-Src Activation

- Dr. Sandra Jacob: Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia

- Prof. George Demetri: Selective kinase inhibition with daily imatinib intensifies toxicity of chemotherapy in patients with solid tumours

- Bettina Dummler: Physiological roles of PKB/Akt isoforms in development and disease

- Bettina Dummler: Life with a Single Isoform of Akt: Mice Lacking Akt2 and Akt3 Are Viable but Display Impaired Glucose Homeostasis and Growth Deficiencies

- Dr. Doriano Fabbro: Effects of PKC412, Nilotinib, and Imatinib Against GIST-Associated PDGFRA Mutants With Differential Imatinib Sensitivity

- Dr. Doriano Fabbro: Allosteric inhibitors of Brc-abl-dependent cell proiferation

- Dr. Doriano Fabbro: Second generation inhibitors of BCRABL for the treatment of imatinibresistant chronic myeloid leukaemia

- Prof. Jim Fagin: Significance of BRAF mutations in papillary thyroid carcinoma: prognostic and therapeutic implications

- Prof. Jim Fagin: Conditional Activation of RET/PTC3 and BRAFV600E in Thyroid Cells Is Associated with Gene Expression Profiles that Predict a Preferential Role of BRAF in Extracellular Matrix Remodeling

- Dr. Pascal Furet: Identification of a New Chemical Class of Potent Angiogenesis Inhibitors Based on Conformational Considerations and Database Searching

- Dr. Pascal Furet: Salicylanilides as inhibitors of the protein tyrosine kinase epidermal growth factor receptor

- Dr. Carlos Garcia-Echeverria: Entry into a New Class of Potent Proteasome Inhibitors Having High Antiproliferative Activity by Structure-Based Design

- Dr. Carlos Garcia-Echeverria: Blocking insulin-like growth factor-I receptor as a strategy for targeting cancer

- Dr. Carlos Garcia-Echeverria: In vivo antitumor activity of NVP-AEW541—A novel, potent, and selective inhibitor of the IGF-IR kinase

- Prof. Susan Gasser: Replisome instability, fork collapse, and gross chromosomal helicase mutations rearrangements arise synergistically from Mec1 kinase and RecQ

- Prof. Susan Gasser: Replication foci dynamics: replication patterns are modulated by S-phase checkpoint kinases in fission yeast

- Prof. Mike Hall: Mutual Antagonism of Target of Rapamycin and Calcineurin Signaling

- Prof. Mike Hall: mTORC2 Caught in a SINful Akt

- Prof. Mike Hall: Regulation of ribosome biogenesis: Where is TOR?

- Alexander Hergovitch: Centrosome-Associated NDR Kinase Regulates Centrosome Duplication

- Prof. Tony Hunter: A not so brief history of the Oncogene Meeting and its Cartoons

- Prof. Nancy Hynes: Targeting ADAMS and ERBBs in lung cancer

- Dr. Heidi Lane: Dual Inhibition ofmTORand Estrogen Receptor Signaling In vitro Induces Cell Death inModels of Breast Cancer

- Prof. David Livingston: The BRCA1/BARD1 Heterodimer Modulates Ran-Dependent Mitotic Spindle Assembly

- Prof. Alexander Levitzki: ATP non-competitive IGF-1 receptor kinase inhibitors as lead anti-neoplastic and anti-papilloma agents

- Prof. Alexander Levitzki: A Novel Substrate Mimetic Inhibitor of PKB/Akt Inhibits Prostate Cancer Tumor Growth in Mice by Blocking the PKB Pathway

- Prof. Nick Lydon: Lessons learned from the development of imatinib

- Dr. Paul Manley: Second generation inhibitors of BCRABL for the treatment of imatinibresistant chronic myeloid leukaemia

- Dr. Paul Manley: Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia

- Prof. Alex Matter: Protein tyrosine kinase inhibitors: new treatment modalities?

- Prof. Adrian Merlo: Combination of sublethal concentrations of epidermal growth factor receptor inhibitor and microtubule stabilizer induces apoptosis of glioblastoma cells

- Prof. Peter J. Parker: The von Hippel–Lindau tumour-suppressor protein interaction with protein kinase Cgamma

- Prof. Peter J. Parker: PKCe-mediated phosphorylation of vimentin controls integrin recycling and motility

- Prof. Tony Pawson: Oncogenic re-wiring of cellular signaling pathways

- Prof. Thomas M. Roberts: PI3 Kinases in Cancer: From Oncogene Artifact to Leading Cancer Target

- Prof. Thomas M. Roberts: The p110alpha isoform of PI3K is essential for polyoma middle T antigen mediated transformation

- Prof. Joseph Schlessinger: Nuclear Signaling by Receptor Tyrosine Kinases: The First Robin of Spring

- Prof. Bill Sellers: Lineage dependency and lineagesurvival oncogenes in human cancer

- Prof. Bill Sellers: High-throughput oncogene mutation profiling in human cancer

- Prof. Bill Sellers: Patterns of somatic mutation in human cancer genomes

- Prof Radek Skoda: Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders

- Prof Radek Skoda: Leukemic blasts in transformed JAK2-V617F positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation

- Prof. Michael Stratton: PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene

- Dr. George Thomas: hvps34, an ancient player, enters a growing game: mTOR Complex1/S6K1 signaling

- Dr. George Thomas: mTOR Complex1–S6K1 signaling: at the crossroads of obesity, diabetes and cancer

- Dr. George Thomas: The mTOR Inhibitor RAD001 Sensitizes Tumor Cells to DNA-Damaged Induced Apoptosis through Inhibition of p21 Translation

- Dr. George Thomas: Nutrient overload, insulin resistance, and ribosomal protein S6 kinase 1, S6K1

- Prof. Alex Ullrich: Nuclear Translocation of the Tumor Marker Pyruvate Kinase M2 Induces Programmed Cell Death

- Prof. Victor Velculescu: Large-scale identification of novel transcripts in the human genome

- Prof. Victor Velculescu: Mutations in a signalling pathway

- Prof. Victor Velculescu: Mutant PIK3CA promotes cell growth and invasion of human cancer cells

- Prof. Victor Velculescu: The Consensus Coding Sequences of Human Breast and Colorectal Cancers

- Prof. Owen Witte: Isolation and functional characterization of murine prostate stem cells

- Prof. Owen Witte: Normal Immune Development and Glucocorticoid-Induced Thymocyte Apoptosis in Mice Deficient for the T-Cell Death-Associated Gene 8 Receptor

- Prof. Michael B. Yaffe: 14-3-3sigma controls mitotic translation to facilitate cytokinesis

- Prof. Michael B. Yaffe: Proteomic screen defines the Polo-box domain interactome and identifies Rock2 as a Plk1 substrate

- Prof. Michael B. Yaffe: p53-Deficient CellsRelyonATM-andATR-Mediated Checkpoint Signaling through the p38MAPK/MK2 Pathway for Survival after DNA Damage